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The use of complementary and alternative medicine in minority populations in 
individuals infected with HIV is prevalent and these cultural practices require laboratory 
confirmation to determine effectiveness. The manipulation of HIV via nutritional 
supplementation could provide insight to the efficacy of cultural remedies.   
Ergothioneine, a compound derived from mushrooms and a naturally occurring 
amino acid, was used as a positive control due to its confirmed ability to decrease HIV 
promoter-driven gene expression via inhibition of the NF-B transcription factor. Four 
herbal remedies, which are purported to prevent or treat HIV infection by Black and 
Latino HIV patients and uninfected individuals, were also tested for antiviral properties.  
Ergothioneine, Hypoxis hemerocallidea, Sutherlandia frutescens, Opuntia ficus-indica, 
and Uncaria tomentosa were liquefied and used to prepare serial dilutions.  The dilutions 
were used to treat CEM-GFP cells in cytotoxicity assays to determine ideal 
concentrations for treatments, that alone (i.e. in the absence of virus) had minimal effects 
on GFP expression.  Once concentrations of each treatment were elected, CEM-GFP cells 
were cultured in the presence of the dilutions, followed 24 hrs. later by HIV infection and 
monitoring for GFP expression. In this system, increased GFP fluorescence signifies 
stimulation of HIV replication, and decreases in GFP fluorescence signifies inhibition of 
HIV replication.  The results suggested that ergothioneine, Hypoxis hemerocallidea, and 
Sutherlandia frutescens prevented HIV proliferation post-infection while Opuntia ficus-
indica and Uncaria tomentosa both stabilized cells prior to infection and inhibited HIV 
proliferation post-infection.
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CHAPTER I 
 
INTRODUCTION 
The use of complementary and alternative medicine in minority populations in 
individuals infected with HIV is prevalent and these cultural practices require laboratory 
confirmation to determine effectiveness1-3. The manipulation of HIV via nutritional 
supplementation could provide insight as to the efficacy of cultural remedies3.  
For this research, we have used the CEM-GFP cell line, which contains an 
engineered GFP gene driven by the HIV long terminal repeat (LTR) promoter, so that 
when they are infected with HIV-1, one can measure the expression of GFP fluorescence 
as a function of HIV activity (since HIV activates its own transcription). Ergothioneine, a 
compound derived from mushrooms and a naturally occurring amino acid, was used as a 
positive control in these studies. Based on the evidence that ergothioneine is a potent 
antioxidant, it is expected that ergothioneine will decrease the activity of reactive oxygen 
species and inhibit the NF-B transcription factor, to inhibit the transcription and 
proliferation of HIV4-8. In ergothioneine-treated HIV-infected CEM-GFP cells, a 
decrease in intensity of GFP expression would signify a decline in HIV activity, 
confirming the expected result, if ergothioneine has antiviral activity. If successful, this 
experimental design and assay would serve as a positive control for the second aim. 
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The design of the ergothioneine assay was repeated to test 4 commonly utilized 
herbal compounds, Hypoxis hemerocallidea, Sutherlandia frutescens, Opuntia ficus-
indica, and Uncaria tomentosa9, 10.  As these herbs are used in Black American and 
Latino American populations11, which have the highest rates of HIV infection in the 
United States, the ratification or denial of their purported role in inhibiting HIV activity is 
necessary information for the future of complementary and alternative medicine in these 
populations9, 10. 
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CHAPTER II 
 
BACKGROUND 
HIV Overview 
The commonly known Human Immunodeficiency Virus (HIV) is a member of the 
genus Lentivirus included in the Retroviridae family8. While lentiviruses include a 
multifaceted group of viruses that afflict animals, HIV is widely known due to its 
involvement in the development of the Acquired Immune Deficiency Syndrome (AIDS) 
in humans8, 13.  
HIV-1, which differs from the HIV-2 strain mainly by the interaction of 
antibodies with the viral envelope glycoproteins, infects the host most commonly via 
binding to the CD4 (cluster of differentiation) receptors of T cells by the gp120 viral 
envelope protein8, 14.  After attachment to the CD4 glycoprotein, there is subsequent 
fusion of the viral envelope with the T cell membrane and entry into the host as a 
ribonucleocapsid8, 15. After entry into the T cell, the HIV nucleic acids are uncoated in 
cytoplasm.  The exposed RNA undergoes reverse transcription to form double stranded 
viral DNA, which accesses the T cell nucleus and is integrated into the host genome8, 16. 
Following integration of the viral DNA, replication, transcription, and translation 
of the T cell genome will facilitate the proliferation of HIV in the host’s system8, 16.  
While antiviral therapies can be directed at any of the aforementioned steps in the HIV  
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infection cycle, the focus of the proposed research pertains to the inhibition of 
transcription. 
 
HIV in Society 
Aside from solely pharmaceutical interventions, a wholesome diet and healthy 
lifestyle is an indispensable component to HIV therapy2. There is a significant correlation 
between malnutrition and the prevalence of HIV in populations1-3, 17. As Colecraft (2008) 
states, “the interaction between HIV/AIDS and food and nutrition security increases 
susceptibility to HIV exposure and infection and HIV/AIDS, in turn, increases 
vulnerability to food insecurity.17” This signifies the necessity of nutritional 
supplementation in prevention and post-infection treatment of HIV/AIDS1-3.  
The correlation between quality of lifestyle and susceptibility to HIV/AIDS is 
indicative of poverty or low income being a contributing factor to likelihood of infection.  
Applying this ideology to populations in the United States, one can expect a higher 
prevalence of HIV infection and AIDS among lower income individuals.  According to 
the National Report Card from the Stanford Center on Poverty and Inequality, Black and 
Hispanic Americans between the ages of 18 and 64 have high percentages of individuals 
living below the poverty line.   By 2012, 27% of Black Americans and 25.6% of Hispanic 
Americans in that age category were living in poverty18.  
Juxtaposing the high poverty rates of Black and Hispanic individuals in the 
United States with the information regarding nutrition and HIV/AIDS, it is 
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understandable that domestic minorities have the highest rates of newly diagnosed 
infections in the country.   
The CDC purports that Black Americans continually have the highest rates of 
HIV/AIDS compared to other races19. Despite only representing 12% of the U.S. 
population in 2010, Blacks accounted for approximately 44% of new infections that 
year11, 19, 20. Additionally, it is expected that approximately 1 in 16 black men and 1 in 32 
black women living in the United States will be diagnosed with HIV in their lifetime21. 
The CDC also gives statistics exemplifying that Hispanic/Latino Americans also suffer 
from high rates of HIV/AIDS in the United States19. In 2010, Latinos represented 16% of 
the population and were plagued with 21% of new infections20.The likelihood for 
infection was 2.9 times higher in Latino males and 4.2 times higher in Latina females 
than their white counterparts in 201011. The death rates of Black and Latino individuals 
with HIV is equally jarring, with over 260,800 Blacks and 96,200 Latinos with AIDS 
diagnoses passing away since the epidemic began19. Due to these statistics, it is crucial to 
focus on these racial groups for antiviral nutritional intervention. 
 
Complementary and Alternative Medicine Use in Minorities 
Complementary and Alternative Medicine (CAM) is very common among 
minority populations in the United States, especially among Black Americans and Latino 
Americans9, 10, 22-24. The prevalence of herbal use and CAM is theorized to be rooted not 
only in cultural practice, but also as a result of discrimination in health care settings.  Due 
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to systematic and internalized racism in American history, many domestic minorities 
develop a sense of mistrust of healthcare providers25.  
While estimates of CAM use in American adults ranges from 29% to 68% of the 
population, the prevalence among Black Americans is estimated at 67.6-71.3% of adults9. 
A 2012 study pertaining strictly to HIV positive Black Americans reflected that of 182 
subjects, 94% of participants used CAM to treat their HIV and 79.7% of participants used 
CAM as a complement to HIV therapy, as opposed to as an alternative23. Similarly, the 
use of CAM is widely prevalent in Latino populations for antiviral purposes. A 2013 
study showed 76% of 113 Latino participants with HIV used some form of CAM in their 
treatment10.  
Whether the commonly utilized herbs and remedies are beneficial or deleterious 
via drug interactions to HIV patients, it is imperative that healthcare providers document 
these treatments so that the proper research can be conducted22.  
 
Ergothioneine 
Ergothioneine is a sulfur-containing amino acid derived from the ergot fungus at 
concentrations of approximately 4 mM and exists in vivo in concentrations between 1 
mM and 2 mM4, 5. Ergothioneine is purported to have antioxidative properties, the actions 
of which would reduce reactive oxygen species (ROS) in the body, leading to the 
eventual inhibition to the function of the NF-B pathway5, 6, 26. Reactive oxygen species 
include superoxide (O2-), nitric oxide (NO), hydroxyl radical (OH.), hydrogen peroxide 
(H2O2), hypochlorous acid (HOCl), and others3, 5. Shortly after infection, these ROS 
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increase, leading to oxidative stress which involves the generation of free radicals that 
contribute to the degradation of DNA and cellular damage3, 6.  
T cell transcription involves activation of the cell, which leads to a myriad of 
intracellular signaling events8, 27.  Activation begins with a receptor-ligand mediated 
signaling event occurring on the plasma membrane.  These interactions include 
interleukin-2 receptor (IL-2R) with the ligand IL-2, T-cell receptor (TCR) in 
collaboration with CD4, or transmembrane passage of molecules such as phorbol 
myristate acetate (PMA).  TCR stimulation results in the activation of tyrosine kinases, 
such as Fyn (p59fyn), ZAP-70, and Lck (p56lck).  This process is likely controlled by 
tyrosine phosphatases, such as CD45.  Once the tyrosine kinases are activated, they are 
capable of phosphorylating various substrates located in the cytosol, leading to chain of 
signaling events often incorporating intermediate molecules8, 27. For example, Ras-Raf 
signaling pathway is initiated by the binding of Grb2 and SOS to Ras, converting it to 
Raf8, 28. The activation of Raf stimulates a cascade of serine-threonine kinases (MAP-
kinase kinase, MAP-kinase, Rsk, and S6 kinase) which continue the signaling pathway 
and lead to the eventual activation of the DNA binding proteins and transcription factors 
which are responsible for the regulation of gene expression.  The phosphorylation and/or 
the proteolysis of the inhibitor of kappa B (IB) dissociates it from nuclear factor kappa 
B (NF-B).  This allows the passage of NF-B across the nuclear membrane into the 
nucleus, where it binds to DNA to activate transcription and subsequently translation8, 27. 
The signal transduction pathway can also be facilitated via the activation of protein 
kinase C (PKC) by PMA.  Once PKC is activated, it stimulates the generation of the 
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secondary messengers diacylglycerol (DAG) and phosponiositol triphosphate (PIP3) 
through the stimulation of phospholipase C (PLC).  This stimulations the mobilization 
of intracellular calcium (Ca2+) and the release of phosphoinositol (PI), which also leads to 
the phosphorylation and/or proteolysis of IB8, 27.  
NF-B binds on the DNA in close proximity to the long terminal repeat region 
(LTR) of the HIV genome.  While the LTR alone can act as its own promoter, early 
mRNA transcription seems to rely mainly on transcription factors, including NFAT, AP-
1, SP-1, and most notably for the aforementioned specified aims, NF-B8, 29. The NF-B 
transcriptional factor and its inhibitor promote the expression of more than 100 target 
genes that are active contributors in the immune response of the host organism26, 30. NF-
B is also responsible for the production of cytokines, which are involved in a plethora of 
cellular activities and therefore essential to host survival26. Since NF-B activation is an 
immediate early (IE) event in the immune system that is triggered quickly and leads to 
strong transcription of several genes, many viruses (including HIV-1) target the NF-B 
pathway in order to achieve enhanced replication, facilitate survival of the host cell, and 
evade immune detection30. It is evident that NF-B is essential, arguably vital, in the 
transcription of HIV-17, 8, 30. For that reason, NF-B is an ideal target for antiviral 
intervention. 
Several studies have examined the antioxidative properties of ergothioneine. 
Ergothioneine was shown to be an active scavenger of hydroxyl radicals, as well as an 
inhibitor of metal ion complexes that allow free radical species to degrade deoxyribose5, 
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31.  Certain ROS such as hydrogen peroxide, while not a free radical itself, can lead to the 
formation of free radicals that readily react with DNA, causing breaks5, 6, 32.  
Ergothioneine also showed activity in binding iron and copper complexes to 
prevent oxidation, which is notable because under high levels of oxidative stress, cellular 
damage or cell death occurs. Additionally, the decrease of ROS due to oxidative stress in 
the cell decreases the amount of single stranded DNA breaks, failing to activate the 
poly(ADP-ribose) polymerase (PARP) complex5, 6. An activation in the PARP complex 
facilitates not only the apoptosis and/or necrosis of T cells, but also the activation of the 
NF-B pathway6. An antioxidant such as ergothioneine can effectively inhibit this 
cascade of events, therefore preventing damage or loss of T cells, as well as deterring the 
proliferation of HIV throughout the host6, 31. In a 2006 experiment examining -
galactosidase activity in pHIVlacZ transfected cells, Xiao et al proved that the NF-B 
transcription factor was inhibited by ergothioneine at M concentrations33. 
 
Cultural Herbal Remedies 
In Black populations, Hypoxis hemerocallidea and Sutherlandia frutescens have 
been popular in treating HIV and concomitant symptoms for roughly a decade.  The use 
and research of the herbal compounds has been promoted by the South African Ministry 
of Health and herbal compounds continue to be used for HIV treatment34. 
In Latino populations, a rich variety of herbal remedies are utilized for a vast 
range of diseases and ailments.  Opuntia ficus-indica (nopal, prickly pear cactus) and 
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Uncaria tomentosa (uña de gato, cat’s claw) are two of the most commonly used herbal 
compounds purported to have antiviral properties and used to treat HIV35.  
 
Hypoxis hemerocallidea 
Hypoxis hemerocallidea, which has the common name “African potato,” is widely 
used in South African and other areas of the world.  It is an antioxidant and is theorized 
to play a role in the immune system9, 34.  Traditional Zulu healers advise use of Hypoxis 
hemerocallidea for urinary infections, heart weakness, tumors, benign prostatic 
hyperplasia, cancer, hyperglycemia, and many more ailments in addition to HIV. Hypoxis 
hemerocallidea is converted to the active form, rooperol, by -glucosidase during 
digestion9, 37, 38. Rooperol is an aglycone that is alleged to be a strong antioxidant9, 37.  
 
Sutherlandia frutescens 
Sutherlandia frutescens has many common names, including “cancer bush,” and 
is used to treat numerous diseases ranging from the common flu and chronic fatigue to 
cancer and HIV9.  It is widely used in South Africa, Lesotho, Namibia, Botswana, and 
around the world. Experimentally, Sutherlandia frutescens has been shown to have 
antiviral, anti-inflammatory, antiviral, antibacterial, and anticancer properties.  The active 
compounds are theorized to be, L-arginine, pinitol, GABA, triterpenes, and flavonol, 
among others.  In addition to HIV, Sutherlandia frutescens is used for infection 
prevention, stomach issues, cancer, and more39. 
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 Opuntia ficus-indica 
Opuntia ficus-indica is used in Mexico and the United States for HIV, 
hypoglycemia, stomach ulcers, diabetes, burns, asthma, indigestion, and other ailments. 
Ascorbic acid, polyphenolic compounds, and flavonoids are believed to be some of the 
most biologically active compounds in the herb.  Opuntia ficus-indica and other closely 
related cacti have exhibited anti-inflammatory, neuroprotective, and antioxidative 
properties experimentally40.  
 
Uncaria tomentosa 
Uncaria tomentosa is primarily utilized in South and Central America.  It is used 
to treat HIV, as well as inflammatory disorders, viral infections, arthritis, gastrointestinal 
illness, as a form of birth control, and to increase white blood cell counts.  It has been 
experimentally proven to increase blood concentration of protease inhibitors.  The active 
compounds are believed to be oxindole alkaloids, quinovic acid glycosides, tannins, 
catechins, procyanidins, plant sterols, and carboxyl alkyl ester
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CHAPTER III 
 
EXPERIMENTAL PREPARATION 
Cell Expansion and Experimental Materials 
CEM-GFP cells were cultured in accordance with the protocol from the NIH 
AIDS Reagent Program based on the work of Gervaix et al in 199742.  The cells were 
removed from storage in liquid nitrogen and warmed to physiological temperature in a 
37°C water bath for 20 minutes.  The reagents (RPMI 40 medium, fetal bovine serum, 
200 mM L-glutamine, and penicillin-streptomycin) were also be warmed in a 37°C water 
bath for 20 minutes.  The cell suspension was prepared in a T-25 tissue culture flask by 
adding 88% RPMI 1640 medium, 10% fetal bovine serum, 1% 200 mM L-glutamine, and 
1% penicillin-streptomycin.  The CEM-GFP cells were added to achieve a 1:10 mixture.  
Cell media was replaced every 2-4 days for maintenance and growth as recommended in 
the aforementioned protocols.  The expansions and passaging were performed in a sterile 
hood and under sterilized conditions.   
The cells were passaged and counted every three to four days to maintain healthy 
and viable cells for experimental use.  In passaging, cells were centrifuged and 
supernatant was removed.   
Powder ergothioneine, CEM-GFP cells, and HIV-1LAI/PBMC were in the 
possession of the Taylor Research Group at the Joint School of Nanoscience and 
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Nanoengineering.  The CEM-GFP cells and HIV-1LAI were acquired from the NIH AIDS 
Reagent Program, along with the applicable protocols. The reagents required for growth 
of the CEM-GFP cells in suspension include RPMI 40 medium, fetal bovine serum, 200 
mM L-glutamine, and penicillin-streptomycin.  These reagents were also in possession of 
the Taylor Research Group.  Hypoxis (African Potato) and Sutherlandia (Cancer Bush) 
were purchased from Lyndsay Wilson of MamaJackal, an online store based in South 
African that sells common African herbs used in teas.  Fresh prickly pear cactus pads and 
Baida Cat’s Claw tea were purchased from SuperGMart, an international food store 
located in Greensboro. -glucosidase was purchased from MP Biomedicals. 
 
Cell Viability  
The viability of cells was measured using the Nexelom Cellometer Vision.  
During the passaging protocol, after cells were pelleted in the centrifuge, cells were 
resuspended in 1 mL of growth media.  20 L of cells suspended in media were 
combined with 20 L of Trypan blue, a stain which colors dead cells, can only entered 
cells with compromised membranes.  The stained cells were loaded into a reading plate, 
which was inserted into the Cellometer Vision.  A readout was produced giving the total 
number of cells, the number of live cells, the number of dead cells, the concentration per 
milliliter of total cells, live cells, and dead cells, and a percentage labeled “viability” 
representing the fraction of live cells to total cells.  This result is based on the number of 
Trypan blue stained cells in the brightfield image. 
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Preparation of Dilutions 
Serial dilutions of ergothioneine, Hypoxis hemerocallidea, Sutherlandia 
frutescens, -Glucosidase, Opuntia ficus-indica, and Uncaria tomentosa were prepared 
prior to beginning experiments.  The dilutions were prepared to reach an ideal 
concentration when combined with 200 L of media already in each well of a 96-well 
plate. 
 
Ergothioneine Dilutions 
Concentrations for ergothioneine dilutions of 6 mM, 5 mM, 4 mM, 3 mM, 2.5 
mM, 2.0 mM, 1.5 mM, 1.0 mM, 0.5 mM, 0.1 mM and 0.05 mM were derived from the 
experimental concentrations of ergothioneine used by Xiao et al33. A 6.0x10-1 M stock 
solution of ergothioneine was prepared by dissolving 137.58 mg of powder ergothioneine 
in 800 L of autoclaved water and adding 200 L of autoclaved water to bring the 
solution to 1 mL.  The 1 mL solution was filtered with a single use needle, a syringe, and 
a 0.22 m syringe-filter. When 2 L of this solution was combined with 200 L of media 
in each well of a 96-well plate, this yielded a 6.0 mM concentration treatment of 
ergothioneine.  The stock solution was used for a serial dilution to produce the other 
desired concentrations.  840 L of 6.0x10-1 M stock solution was combined with 160 L 
of autoclaved water to produce a 5.0x10-1 M solution of ergothioneine which produced 1 
mL of a 5.0 mM solutions of ergothioneine when 2 L of the solution was added to a 
well containing 200 L media.  800 L of the 5.0x10-1 M ergothioneine solution was 
combined with 200 L of autoclaved water to produce 1 mL of a 4.0x10-1 M 
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ergothioneine solution that yielded a 4.0 mM treatment when 2 L of the solution was 
added to well containing 200 L of media. 750 L of the 4.0x10-1 M ergothioneine 
solution was combined with 250 L of autoclaved water to produce 1 mL of a 3.0x10-1 M 
ergothioneine solution that yielded a 3.0 mM treatment when 2 L of the solution was 
added to well containing 200 L of media. 840 L of the 3.0x10-1 M ergothioneine 
solution was combined with 160 L of autoclaved water to produce 1 mL of a 2.5x10-1 M 
ergothioneine solution that yielded a 2.5 mM treatment when 2 L of the solution was 
added to well containing 200 L of media. 800 L of the 3.0x10-1 M ergothioneine 
solution was combined with 200 L of autoclaved water to produce 1 mL of a 2.0x10-1 M 
ergothioneine solution that yielded a 2.0 mM treatment when 2 L of the solution was 
added to well containing 200 L of media. 750 L of the 2.0x10-1 M ergothioneine 
solution was combined with 250 L of autoclaved water to produce 1 mL of a 1.5x10-1 M 
ergothioneine solution that yielded a 1.5 mM treatment when 2 L of the solution was 
added to well containing 200 L of media. 667 L of the 1.5x10-1 M ergothioneine 
solution was combined with 333 L of autoclaved water to produce 1 mL of a 1.0x10-1 M 
ergothioneine solution that yielded a 1.0 mM treatment when 2 L of the solution was 
added to well containing 200 L of media. 500 L of the 1.0x10-1 M ergothioneine 
solution was combined with 500 L of autoclaved water to produce 1 mL of a 0.5x10-1 M 
ergothioneine solution that yielded a 0.5 mM treatment when 2 L of the solution was 
added to well containing 200 L of media. 200 L of the 0.5x10-1 M ergothioneine 
solution was combined with 800 L of autoclaved water to produce 1 mL of a 0.1x10-1 M 
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ergothioneine solution that yielded a 0.1 mM treatment when 2 L of the solution was 
added to well containing 200 L of media. 500 L of the 0.1x10-1 M ergothioneine 
solution was combined with 500 L of autoclaved water to produce 1 mL of a 0.05x10-1 
M ergothioneine solution that yielded a 0.05 mM treatment when 2 L of the solution 
was added to well containing 200 L of media.  
 
 
 
Figure 1. Preparation of Serial Dilutions of Ergothioneine 
Hypoxis hemerocallidea, Sutherlandia frutescens, and -Glucosidase Dilutions 
 
Dilution concentrations for Hypoxis hemerocallidea and Sutherlandia frutescens 
were based around the values for experimental concentrations of teas utilized by Si et 
al43. A stock solution of the same concentration of Hypoxis hemerocallidea and 
Sutherlandia frutescens was prepared by measuring 6.2510 g of dried Hypoxis 
hemerocallidea and 6.2521 g of dried Sutherlandia frutescens (approximately 6250 mg) 
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and boiling each in 50 mL of autoclaved water in a 150 mL beaker for 20 minutes.  After 
cooling for 10 minutes, a hand sieve was used to strain the boiled herb and collect the tea.  
More autoclaved water was added to bring the final volume of the tea to 100 mL.  This 
gave a stock solution with a concentration of 62.5 mg/mL.  1 mL of the stock solution 
was collected and filtered.  800 L was taken to give a concentration of 50 mg/800 L, 
which became 50 mg/mL when 2 L of the solution was added to a well containing 200 
L of media.  Another 1 mL of the stock solution was filtered and 800 L was taken.  
The 800 L with concentration 50 mg/mL was combined with 200 L of autoclaved 
water to produce 1 mL of a 40 mg/mL solution that yielded a 40g/mL treatment when 2 
L of the solution was added to a well containing 200 L of media.  750 L of the 40 
mg/800 L solution was combined with 250 L of autoclaved water to produce 1 mL of a 
30 mg/800 L solution that yielded a 30 mg/mL treatment when 2 L of the solution was 
added to a well containing 200 L of media. 667 L of the 30 mg/800 L solution was 
combined with 333 L of autoclaved water to produce 1 mL of a 20 mg/800 L solution 
that yielded a 20 mg/mL treatment when 2 L of the solution was added to a well 
containing 200 L of media. 500 L of the 20 mg/800 L solution was combined with 
500 L of autoclaved water to produce 1 mL of a 10 mg/800 L solution that yielded a 
10 mg/mL treatment when 2 L of the solution was added to a well containing 200 L of 
media. 500 L of the 10 mg/800 L solution was combined with 500 L of autoclaved 
water to produce 1 mL of a 5 mg/800 L solution that yielded a 5 mg/mL treatment when 
2 L of the solution was added to a well containing 200 L of media. 200 L of the 5 
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mg/800 L solution was combined with 800 L of autoclaved water to produce 1 mL of a 
1 mg/800 L solution that yielded a 1 mg/mL treatment when 2 L of the solution was 
added to a well containing 200 L of media.  In order to convert Hypoxis hemerocallidea 
to the active rooperol form, equal dilutions of -Glucosidase were prepared in the 
aforementioned manner and added along with the corresponding concentration of 
Hypoxis hemerocallidea.  This method of action was influenced by the precedent of 
adding equal concentrations of Hypoxis hemerocallidea and -Glucosidase utilized by 
Boukes in his 2010 experiments44.  
 
 
Figure 2. Preparation of Serial Dilutions of Hypoxis hemerocallidea, Sutherlandia frutescens 
and -Glucosidase 
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Opuntia ficus-indica Dilutions 
Three pads of Opuntia ficus-indica were purchased and weighed to determine the 
general mass of a prickly pear cactus pad.  The three pads weighed 73.5824 g, 89.0023 g, 
and 107.0625 g.  From these weights, the desired dilution concentrations of 100 g/250 
mL, 75 g/ 250 mL, 50 g/250 mL, 25 g/250 mL, 10 g/250 mL, 5 g/250 mL and 1 g/250 
mL were developed.  250 mL was used as the measurement of 1 metric cup, as there is 
variation between a “customary cup” and a “legal cup” in the United States45. A stock 
solution of prickly pear cactus was prepared by placing 40.0194 g of a pad stripped of 
needles in a blender with 100 mL of autoclaved water for approximately 5 minutes on 
varied settings until all visible particles were entirely obliterated.  A hand sieve was used 
to strain large particles out of the juice, meant to mimic a “licuado,46” and 100 mL of 
juice was used.  Due to the relatively large particles of prickly pear cactus in the sieved 
solution, this solution was not filtered to be sterile to prevent extricating biologically 
active compounds. 100 mL of juice containing approximately 40 g of prickly pear cactus 
is equivalent to a 100 g/249.8 mL solution.  When 2 L of this solution was added to a 
well containing 200 L of media, a treatment of 100 g/250 mL, or 100 g of prickly pear 
cactus per cup of water, was produced.  750 L of the 40 g/100 mL stock solution was 
combined with 250 L of autoclaved water to p•roduce 1 mL of a 30 g/ 100 mL solution.  
This was the equivalent of a concentration of 75 g/249.8 mL solution that yielded a 75 g/ 
250 mL treatment when 2 L of the solution was added to a well containing 200 L of 
media.  667 L of the 30 g/100 mL solution was combined with 333 L of autoclaved 
water to produce 1 mL of a 20 g/ 100 mL solution.  This was the equivalent of a 
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concentration of 50 g/249.8 mL solution that yielded a 50 g/ 250 mL treatment when 2 
L of the solution was added to a well containing 200 L of media.  500 L of the 20 
g/100 mL solution was combined with 500 L of autoclaved water to produce 1 mL of a 
10 g/ 100 mL solution.  This was the equivalent of a concentration of 25 g/249.8 mL 
solution that yielded a 25 g/ 250 mL treatment when 2 L of the solution was added to a 
well containing 200 L of media.  400 L of the 10 g/100 mL solution was combined 
with 600 L of autoclaved water to produce 1 mL of a 4 g/ 100 mL solution.  This was 
the equivalent of a concentration of 10 g/249.8 mL solution that yielded a 10 g/ 250 mL 
treatment when 2 L of the solution was added to a well containing 200 L of media.  
500 L of the 4 g/100 mL solution was combined with 500 L of autoclaved water to 
produce 1 mL of a 2 g/ 100 mL solution.  This was the equivalent of a concentration of 5 
g/249.8 mL solution that yielded a 5 g/ 250 mL treatment when 2 L of the solution was 
added to a well containing 200 L of media.  200 L of the 2 g/100 mL solution was 
combined with 800 L of autoclaved water to produce 1 mL of a 0.4 g/ 100 mL solution.  
This was the equivalent of a concentration of 1 g/249.8 mL solution that yielded a 1 g/ 
250 mL treatment when 2 L of the solution was added to a well containing 200 L of 
media.   
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Figure 3. Preparation of Serial Dilutions of Opuntia ficus-indica. 
Uncaria tomentosa Dilutions 
Uncaria tomentosa was sold as a Baida tea product labeled “Cat’s Claw” and 
packaged in individual tea bags.  This packaging quantity was used to develop the desired 
concentrations of 4 bags/250 mL, 3 bags/250 mL, 2 bags/250 mL, 1 bag/250 mL, ½ bag/ 
250 mL,  bag/250 mL, and ¼ bag/250 mL.  To prepare a stock solution of 4 
bags/249.8 mL, a 150 mL beaker was filled with 50 mL of autoclaved water.  One bag of 
cat’s claw was placed in the water and boiled for 20 minutes.  After cooling for 10 
minutes, the bag was strained of liquid with a spatula and the final volume of the tea was 
brought up to 62.3 mL.  This yielded a concentration of 1 bag/ 62.5 mL, or 1 bag/250 
mL, when 2 L of the solution was added to a well containing 200 L of media. 1 mL of 
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the stock solution was filtered and used for serial dilutions. 749 L of the 1 bag/62.3 mL 
stock solution was combined with 251 L of autoclaved water to produce 1 mL of a 1 
bag/83.13 mL solution.  This was the equivalent of a concentration of 3 bags/249.8 mL 
solution that yielded a 3 bags/250 mL solution when 2 L was added to a well containing 
200 L of media. 666 L of the 1 bag/83.13 mL stock solution was combined with 334 
L of autoclaved water to produce 1 mL of a 1 bag/124.8 mL solution.  This was the 
equivalent of a concentration of 2 bags/249.8 mL solution that yielded a 2 bags/250 mL 
solution when 2 L was added to a well containing 200 L of media.  500 L of the 1 
bag/124.8 mL stock solution was combined with 500 L of autoclaved water to produce 
1 mL of a 1 bag/249.8 mL solution.  This was the equivalent of a concentration of 1 
bag/249.8 mL solution that yielded a 1 bag/250 mL solution when 2 L was added to a 
well containing 200 L of media. 500 L of the 1 bag/249.8 mL stock solution was 
combined with 500 L of autoclaved water to produce 1 mL of a 1 bag/499.8 mL 
solution.  This was the equivalent of a concentration of ½ bags/249.8 mL solution that 
yielded a ½ bags/250 mL solution when 2 L was added to a well containing 200 L of 
media.  667 L of the 1 bag/249.8 mL stock solution was combined with 333 L of 
autoclaved water to produce 1 mL of a 1 bag/749.8 mL solution.  This was the equivalent 
of a concentration of  bags/249.8 mL solution that yielded a  bags/250 mL solution 
when 2 L was added to a well containing 200 L of media. 750 L of the 1 bag/749.8 
mL stock solution was combined with 250 L of autoclaved water to produce 1 mL of a 1 
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bag/999.8 mL solution.  This was the equivalent of a concentration of ¼ bags/249.8 mL 
solution that yielded a ¼ bags/250 mL solution when 2 L was added to a well 
containing 200 L of media.  
 
 
Figure 4. Preparation of Serial Dilutions of Uncaria tomentosa 
After all dilutions were prepared, they were stored in the lab in a refrigerator at 
approximately 4°C. 
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CHAPTER IV 
 
ASSAYS TO DETERMINE CYTOTOXICITY OF TREATMENTS AND TO 
ELECT APPROPRIATE CONCENTRATIONS FOR EXPERIMENTAL USE 
In order to ensure the herbal treatments didn’t have significant effects on the 
viability of the CEM-GFP cells, cytotoxicity assays were performed with various 
concentrations of each treatment.  The objective of these assays was to examine various 
concentrations of each treatment and select the concentration that had little effect on the 
GFP expression in comparison to the control trials.   
 
Materials 
96-well plates were seeded with CEM-GFP cells at approximately 30,000 cells 
per well in 200 L of media.  After approximately 24 hours, the cells were treated with 
varying concentrations of chemical or herbal dilutions.  2 L of the dilution was placed in 
each well.  24 hours after adding treatments, the plates were read by the BioTek Synergy 
Mx for three to four days. For the preparation of each plate, the following calculations 
were used. 
 
 
30,000 cells x 96 wells = 2,880,000 cells total 
200 L media x 96 wells = 19,200 L media total 
19,200 L  19.2 mL 
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From these calculations, the ideal concentration of 2.88x106 cells in 22 mL of 
media was derived for seeding plates. 
 
Methods 
To evaluate appropriate concentrations of each treatment, cytotoxicity assays 
were performed with 96-well plates, of which the BioTek readouts were analyzed. 
 
Ergothioneine Cytotoxicity Assay 
 
For the ergothioneine cytotoxicity assay, a culture of CEM-GFP cells with a 
viability of 99.4% was used.  The Cellometer determined that the concentration of live 
cells was 1.75x107 cells/mL.  In order to seed the 96-well plate with 30,000 cells in 200 
L of media per well, the following calculations were performed. 
 
 
c1v1 = c2v2 
(1.75x107 cells/mL)(v1) = (2.88x106 cells/22 mL)(22 mL) 
v1 = 0.16457143 mL  165 L of cells 
 
 
165 L of cells was taken from the suspension and added to 22 mL of media and 
mixed thoroughly via inversion.  A 96-well plate was seeded with 200 L of media in 
each well.  Each of the 12 columns of the well plate contained a different concentration 
of ergothioneine.  The first column served as a control with no treatment added while the 
remainder of the columns were treated with an increasing concentration of the 
ergothioneine dilution.  
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Table 1. 96-Well Plate Experimental Setup for the Ergothioneine Cytotoxicity Assay 
 
 
 
Hypoxis hemerocallidea (with -Glucosidase), Opuntia ficus-indica, and Uncaria 
tomentosa Cytotoxicity Assays 
 
For the Hypoxis hemerocallidea with -Glucosidase, Opuntia ficus-indica, and 
Uncaria tomentosa cytotoxicity assays, a culture of CEM-GFP cells with a viability of 
98.2% was used for all three assays.  The Cellometer determined that the concentration of 
live cells was 3.57x107 cells/mL.  In order to seed the three 96-well plates with 30,000 
cells in 200 L of media per well, the following calculations were performed.  
 
 
30,000 cells x 96 wells x 3 plates = 8,640,000 cells total 
200 L media x 96 wells x 3 plates = 57,600 L media total 
57,600 L  57.6 mL 
 
 
From these calculations, the ideal concentration of 8.64x106 cells in 60 mL of 
media was derived for seeding plates.  
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c1v1 = c2v2 
(3.57x107 cells/mL)(v1) = (8.64x106 cells/60 mL)(60 mL) 
v1 = 0.2420168067 mL  242 L of cells 
 
 
242 L of cells was taken from the suspension and added to 60 mL of media and 
mixed thoroughly via inversion.  Three 96-well plates were seeded with 200 L of media 
in each well.  Each of the 8 rows of each well plate contained a different concentration of 
Hypoxis hemerocallidea (with -Glucosidase), Opuntia ficus-indica, and Uncaria 
tomentosa.  The first row of each plate served as a control with no treatment added while 
the remainder of the rows were treated with an increasing concentration of the each 
dilution. 
 
 
Table 2. 96-Well Plate Experimental Setup for the Hypoxis hemerocallidea with -Glucosidase 
Cytotoxicity Assay 
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Table 3. 96-Well Plate Experimental Setup for the Opuntia ficus-indica Cytotoxicity Assay 
 
 
 
Table 4. 96-Well Plate Experimental Setup for the Uncaria tomentosa Cytotoxicity Assay 
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Sutherlandia frutescens Cytotoxicity Assay 
For the Sutherlandia frutescens cytotoxicity assay, a culture of CEM-GFP cells 
with a viability of 80.4% was used.  The Cellometer determined that the concentration of 
live cells was 2.38x106 cells/mL.  In order to seed the 96-well plate with 30,000 cells in 
200 L of media per well, the following calculations were performed. 
 
 
c1v1 = c2v2 
(2.38x106 cells/mL)(v1) =  (2.88x106 cells/22 mL)(22 mL) 
v1 = 1.210084034 mL  1210 L of cells 
 
 
Since 1 mL of cells at the aforementioned concentration was available, it was not 
possible to seed the 96-well plate with 30,000 cells per well.  Alternatively, calculations 
were performed to seed the 96-well plate with 25,000 cells in 200 L of media. 
 
 
25,000 cells x 96 wells = 2,375,000 cells total 
200 L media x 96 wells = 19,200 L media total 
19,200 L  19.2 mL 
 
 
From these calculations, the ideal concentration of 2.375x106 cells in 60 mL of 
media was derived for seeding plates.  
 
 
c1v1 = c2v2 
(2.38x106 cells/mL)(v1) = (2.375x106 cells/22 mL)(22 mL) 
v1 = 0.9978991597 mL  998 L of cells 
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998 L of cells was taken from the suspension and added to 22 mL of media and 
mixed thoroughly via inversion.  A 96-well plate was seeded with 200 L of media in 
each well.  Each of the 8 rows of the well plate contained a different concentration of 
Sutherlandia frutescens.  The first row served as a control with no treatment added while 
the remainder of the rows were treated with an increasing concentration of the 
Sutherlandia frutescens dilution. 
 
 
Table 5. 96-Well Plate Experimental Setup for the Sutherlandia frutescens Cytotoxicity Assay 
 
 
 
 
Results 
Based on the readouts generated by the BioTek Synergy Mx, the GFP expression 
values for each dilution were averaged for each day.  The averages of each dilution were 
used to assess the trends in viability over the reading window.  BioTek readouts for the 
results of the ergothioneine (EGT) cytotoxicity assay for days 1-4 are provided in 
Appendix A in tables 12-14.  The readouts for the Hypoxis hemerocallidea (AP), 
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Sutherlandia frutescens (CB), Opuntia ficus-indica (PPC), and Uncaria tomentosa (CC) 
cytotoxicity assays are also provided in Appendix A, with tables 15-17 representing days 
1-3 for Hypoxis hemerocallidea, tables 18-21 representing days 1-4 for Sutherlandia 
frutescens, tables 22-24 representing days 1-3 for Opuntia ficus-indica, and tables 25-27 
representing days 1-3 for Uncaria tomentosa. Each readout depicts numbers in the wells 
of the 96-well plate that signify the GFP expression in relative fluorescence units (RFUs).  
A drastic decrease in GFP expression in comparison to the values for the control trials 
was regarded as cell death, meaning the concentration decreased the viability of the cells 
in that well.  The graphs for the analysis of the BioTek readouts are provided in 
Appendix B with Figures 10, 12, and 14 representing the daily readings for ergothioneine 
and Figures 11, 13, and 15 representing the averages of daily trials for ergothioneine.  
Figure 16 represents the expression trends for the ergothioneine cytoxicity assay.  
Additionally, Figures 17, 19, and 21 represent the daily readings for Hypoxis 
hemerocallidea with Figures 18, 20, and 22 representing the averages of daily trials.  
Figure 23 represents the expression trends for the Hypoxis hemerocallidea cytotoxicity 
assay. Figures 24, 26, 28, and 30 represent the daily readings for Sutherlandia frutescens 
with Figures 25, 27, 29, and 31 representing the averages of daily trials.  Figure 32 
represents the expression trends for the Sutherlandia frutescens cytotoxicity assay. 
Figures 33, 35, and 37 represent the daily readings for Opuntia ficus-indica with Figures 
34, 36, and 38 representing the averages of daily trials.  Figure 39 represents the 
expression trends for the Opuntia ficus-indica cytotoxicity assay. Figures 40, 42, and 44 
represent the daily readings for Uncaria tomentosa with Figures 41, 43, and 45 
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representing the averages of daily trials.  Figure 46 represents the expression trends for 
the Uncaria tomentosa cytotoxicity assay. 
After examination of the trends in viability and the difference between the 
average GFP expression of treated cells and the control GFP expression, dilutions of each 
treatment were selected for further experimentation.  Selection criteria involved dilutions 
that yielded an average GFP expression readout close to the control trials over the reading 
period, as well as the highest concentration of treatment that could be given without 
significantly lowering GFP expression, which was interpreted as cell death.  Based on 
these criteria, the concentrations of each dilution were selected to be 0.1 mmol for 
ergothioneine, 5 mg/mL for Hypoxis hemerocallidea, 1 mg/mL for Sutherlandia 
frutescens, 10 g/250 mL for Opuntia ficus-indica, and ½ bag/250 mL for Uncaria 
tomentosa. 
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CHAPTER V 
 
MTT ASSAY TO VERIFY CELL VIABILITY WITH SELECTED HERBAL 
CONCENTRATIONS 
 
 
While the cytotoxicity assays assisted in electing appropriate concentrations of 
treatments, the assays were only designed to give GFP expression.  A change in GFP 
expression could be attributed to various factors; however the use of an MTT assay could 
verify that changes in GFP expression were not affected by cell viability.  The purpose of 
an MTT assay is to ascertain cell viability through a colorimetric experiment, which 
functions by exposing the cells to tetrazolium dye and monitoring for color changes 
linked to the formation of formazan crystals47.  The reaction is facilitated by 
mitochondrial dehydrogenase enzymes and monitored by the change of color in the wells, 
which is more significant when there are a greater number of viable cells47. 
 
Materials 
The cytotoxicity assay was performed with a Vybrant MTT Cell Proliferation 
Assay Kit from Life Technologies . The kit contained 10 vials of Component A, each of 
which contained 5 mg of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT, MW = 414) and 10 vials of Component B, each of which contained  1 g of sodium 
dodecyl sulfate (SDS, MW = 288).  The materials were stored at 4oC in a dry, dark area. 
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Required materials not included in the kit included sterile phosphate-buffered saline 
(PBS), sterile 0.01 M hydrogen chloride (HCl), and RPMI 1640 without phenol red, all of 
which were in possession of the Taylor Research Group48.  
 
Methods 
The experimental protocol for the MTT assay found on the Life Technologies 
website was closely adhered to.   
 
Reagent and Cell Preparation 
To prepare the reagents for the experiment, 1 mL of PBS was added to 1 vial of 
Component A, yielding a 12 mM stock solution of MTT.  The solution was mixed by 
vortexing. Additionally, 10 mL of 0.01 M HCl was added to 1 vial of Component B, 
yielding an SDS solution, which was mixed by gentle inversion. 
In order to perform the assay, a 96-well plate seeded with CEM-GFP cells 
cultured in RPMI complete media without phenol red was needed.  Based on the protocol 
provided by Life Technologies, the desired experimental design called for 10,000 cells in  
200 L media per well.  
 
 
10,000 cells/well x 72 wells = 720,000 cells total 
200 L media/well x 72 wells = 14,400 L media total 
14,400 L  14.4 mL 
 
 
 
 
 35  
     
CEM-GFP cells used for the MTT assay were obtained from a cell culture that 
was determined to contain 6.55x106 live cells with a viability of 51.2%.  The following 
calculations were used to seed a 96-well plate for the assay. 
 
 
c1v1 = c2v2 
(6.55x106 cells/mL)(v1) = (7.2x105 cells/15 mL)(15 mL) 
v1 = 0.1099236641 mL  110 L  
 
 
110 L of cells was taken from suspension and combined with 15 mL of phenol 
red free media.  This suspension of cells was used to seed 72 wells of a 96-well plate with 
10,000 cells per well in 200 L media.  Approximately 24 hours later, the previously 
determined dilutions of each treatment were added to five separate rows, with the first 
row serving as a control.  48 hours after the initial seeding of the plate, the MTT assay 
was performed. 
 
Table 6. 96-Well Plate Setup for MTT Assay. EGT – Ergothioneine, AP – Hypoxis 
hemerocallidea (African potato), CB – Sutherlandia frutescens (Cancer Bush), PPC – 
Opuntia ficus-indica (Prickly Pear Cactus), CC – Uncaria tomentosa (Cat’s Claw) 
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Labeling Cells 
Since CEM-GFP cells are suspension cells, the microplate was centrifuged at 
1000 RPM for 5 minutes.  The media was removed from each well and replaced with 100 
L of fresh RPMI media.  An additional row of 100 L of media alone was added to the 
plate to serve as a negative control. 10 L of the 12 mM MTT stock solution was added 
to each well and the plate was incubated at 37oC for 4 hours.  After the incubation, 100 
L of the SDS-HCl solution was added to each well and mixed in thoroughly with the 
pipette.  The plate was incubated for another 4 hours at 37oC and after removal, each well 
was again mixed thoroughly with a pipette.  The plate was read in the BioTek Synergy 
Mx at an absorbance of 570 nm. 
 
Results 
The readout from the BioTek Synergy Mx was acquired and analyzed in order to 
determine whether the selected concentrations were appropriate for further 
experimentation.  
 
 
 
 
 
 
 
 
 37  
     
Table 7. BioTek Absorbance Readout for MTT Assay in Absorbance Units (AUs). 
Highlighted Wells Represent Trials that were Considered Outliers and Not Used for 
Calculation of Mean, Standard Deviation, and Standard Error. 
 
 
 
 
After outliers were eliminated from calculations, the absorbance of each treatment 
for every trial was assessed. The averages for each treatment were also assessed.  
 
 
 
 
Figure 5. Graph of BioTek Readouts for MTT Assay for Each Day of Reading 
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Figure 6. Graph of BioTek Readouts for MTT Assay Averages for Each Day of Reading 
 
 
From the analysis of the BioTek readout, it was determined that the selected 
dilutions of treatments did not negatively affect the viability of the cells, due to the 
average absorbance of treated cells being higher than that of the control.  In an MTT 
assay, the higher the value in absorbance units correlates to the ability of viable cells to 
metabolize the tetrazolium dye47.  The reading, performed at 570 nm, measures 
absorbance for the presence of the salt product from the reaction with the dye. Since a 
higher absorbance correlates to cell viability and the control trials of CEM-GFP cells 
alone produced an average readout of approximately 0.189 absorbance units, the 
concentrations of dilutions used to treat the cells were deemed appropriate due to higher 
average readouts in absorbance.  Additionally, there was an implication that some of the 
herbal treatments stabilized cells in a way that promoted a higher viability than untreated 
cells, resulting in a higher concentration of CEM-GFP cells in the experimental wells. 
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It is important to keep in mind that the increased viability seen in the herbal 
treatments of ergothioneine, Hypoxis hemerocallidea, Sutherlandia frutescens, Opuntia 
ficus-indica, and Uncaria tomentosa, these results are vital in the assessment of the effect 
of herbal treatments on HIV infected cells.  The increased number of CEM-GFP cells that 
is achieved through unknown mechanisms of the herbal treatments could possibly affect 
the GFP expression readouts generated by the BioTek. 
These results will be reiterated in the conclusion as a function of explaining 
limitations and possible discrepancies in the GFP expression readouts for the experiment 
investigation the action of the herbal remedies when used to treat CEM-GFP cells prior to 
HIV infection. 
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CHAPTER VI 
 
EXPERIMENTAL INVESTIGATION OF EFFECT OF HERBAL TREATMENTS 
ON CELLS PRIOR TO HIV INFECTION 
 
 
After it was confirmed that the herbal treatments were not decreasing the viability 
of the cells or significantly effecting the function of the GFP protein, the selected 
concentrations of herbal treatment were tested for effectiveness with live HIV.  As the 
cells were treated before viral infection, the ability of the herbal treatments to prevent 
entry of HIV into the cell or inhibition of HIV proliferation was monitored through 
analysis of GFP expression. 
 
Materials 
 
Powdered polybrene and HIV-1LAI was previously acquired from the NIH AIDS 
Reagent Program by the Taylor Research Group. Polybrene (hexadimethrine bromide) is 
a polymer that is commonly used to increase susceptibility of cells to a retroviral 
infection in cell culture49. 
 
Methods 
 
In order to perform the assay, 72 wells of a 96-well plate seeded with CEM-GFP 
cells cultured in RPMI complete media and treated with polybrene was needed. 
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Plating and Treatment 
 
To plate a 96-well plate with 30,000 cells in 200 L per well in 72 wells, the 
following calculations were performed.  
30,000 cells/well x 72 wells = 2,160,000 cells total 
200 L media/well x 72 wells = 14,400 L media total 
14,400 L  14.4 mL 
 
 
Based on these calculations, it was decided that the cells would be prepared in 15 
mL of media. CEM-GFP cells used for the HIV assay were obtained from a cell culture 
that was determined to contain 6.55x106 live cells with a viability of 51.2%.  The 
following calculations were used to seed 72 wells of a 96-well plate for the assay.  
 
 
c1v1 = c2v2 
(6.55x106 cells/mL)(v1) = (2.16x106 cells/15 mL)(15 mL) 
v1 = 0.329770924 mL  330 L  
 
 
330 L of cells was taken from suspension and combined with 15 mL of media.  
The cells were then treated with a previously prepared stock solution of polybrene with a 
concentration of 500 g/mL of media.  The stock solution was prepared by dissolving 
100 mg of powder polybrene into 200 mL of RPMI 1640, without FBS, L-Glutamine, or 
penicillin-streptomycin.  After preparation, the mixture was sterilized with a 0.2 L 
filtration unit and aliquoted into 15 mL tubes.  The stock solution was stored at 2-4oC 
pending use.  After the 330 L of CEM-GFP cells were taken from suspension and 
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combined with 15 mL of media, polybrene was added according to the predetermined 
ratio of 40 L polybrene per 10x106 cells currently under use by the Taylor Research 
Group. 
40 L of polybrene/ 10x106 cells = x L of polybrene/2.16x106 cells 
x = 8.64 L of polybrene 
The cell suspension was treated with 8.64 L of polybrene and mixed by gentle 
inversion.  This suspension of cells was used to seed 72 wells of a 96-well plate with 
30,000 cells per well in 200 L media.  Approximately 48 hours later, the previously 
determined dilutions of each treatment were added to five separate rows, with the first 
row serving as a control.  72 hours after the initial seeding of the plate, the cells were 
infected with HIV. 
 
HIV Infection 
 
As treatment with polybrene represents Day 0, on Day 3 (72 hours) after 
polybrene treatment, the plated cells were infected with HIV.  Based on previous research 
conducted by the Taylor Research Group, a standard of 1 L of live virus per 10,000 
cells was used to determine the amount of live virus needed.  With the guidance of 
mentor Lakmini Premdasa, the plated cells were estimated to be at approximately 
100,000 CEM-GFP cells per well, requiring 10 L of cells for each well.  The following 
calculations were performed in order to prepare the HIV particles for infection. 
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1 L of virus per 10,000 cells 
100,000 cells per well  10 L of virus per well 
72 wells x 10 L of virus = 720 L virus total 
100 L of media x 72 wells = 7200 L of media  7.2 mL of media 
Based on calculations, 800 L of cells was mixed with 8.0 mL of media and 100 
L of media containing virus was pipetted into each well.  The cells were incubated and 
read for 7 days following infection. 
 
 
Table 8. 96-Well Plate Experimental Setup for HIV Experiment 
 
 
 
 
Results 
Readings for 7 days following the infection were taken with the BioTek Synergy 
Mx. BioTek readouts are provided in Appendix A with Tables 28-34 representing the 
GFP expression readouts for reading days 1-7.  Graphs for each day and daily averages 
are provided in Appendix B, with Figures 47, 49, 51, 53, 55, 57, and 59 representing the 
daily readings for days 1-7 and Figures 48, 50, 52, 54, 56, 58, and 60 representing the 
averages derived from each trail on days 1-7 . Averages for each day were also assessed 
for trends. 
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Figure 7. Graph of HIV Experiment Trends for Each Day of Reading 
 
 
 
 
Figure 8. Graph of HIV Experiment Trends for Each Day of Reading, Including Control 
CEM-GFP Cells from Cytotoxicity Experiments 
 
 
The trend graphs for the HIV experiment signify some protective ability of the 
experimental herbal treatments in preventing infection or stabilizing cellular stress in the 
first few days of active infection.  The peak at day 4 could represent more viable cells in 
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the experimental wells in comparison to the control due to the higher GFP expression on 
that day by the cells treated with herbal remedies.  After day 4, the control trials decrease 
gradually, signifying cell death.  However the rapid decrease in GFP expression 
exemplified by Hypoxis hemerocallida, Sutherlandia frutescens, Opuntia ficus-indica, 
and Uncaria tomentosa implies some antiviral activity or inhibition in viral propagation 
within those wells.  However this could also be a function of the increased viability 
facilitated by these herbal treatments that was demonstrated in the MTT assay.
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CHAPTER VII 
 
CONCLUSION 
 
 
Summary 
Several conclusions can be drawn from the BioTek readout trends.  All of GFP 
expressions exceeded the maximum for previous uninfected, untreated CEM cells, 
confirming a successful HIV infection.  The peak exhibited at Day 4 by nearly every 
treatment corresponds with that day being the height of GFP expression and likely the 
point at which all cells are infected with virus42. The control, untreated CEM-GFP cells 
infected with HIV, showed a general decline in GFP expression throughout the 7 days, 
signifying cell death over time.   
 
Ergothioneine  
Cells treated with ergothioneine showed a gradual increase of GFP expression 
leading up to Day 4 and a decrease in expression following that day.  While this could 
signify cell death after peak infectivity, given what is known about the inhibition of the 
NF-B transcription factor, the decrease in expression could also be interpreted as a 
decrease in viral activity due to hindered transcription.  This conclusion is difficult to 
make due to the trend line for ergothioneine corresponding so closely to the trend line for 
the negative control.  However, the lower levels of GFP expression in the ergothioneine 
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treated cells prior to Day 4 could speak to ergothioneine’s properties as an antioxidant 
and imply a role in stabilizing cells exposed to HIV and the closeness to the negative 
control trendline could signify that several other conclusions.  These conclusions include, 
but are not limited to, the possibility that ergothioneine is not as effective in inhibition 
HIV as previously hypothesized or that while the NF-κB transcription factor is inhibited 
by ergothioneine, there are other transcription factors or cellular mechanisms compensate 
and carry out viral transcription through other means. 
 
Cultural Herbal Remedies 
The results for Hypoxis hemerocallidea, Sutherlandia frutescens, Opuntia ficus-
indica, and Uncaria tomentosa exhibit similar trends and imply that all herbal remedies 
provide some degree of stability to the cell in the early stages of HIV infection.  The GFP 
expression on Day 4 of reading was higher than the experimental control, however for 
reading Days 5-7, all herbal remedies returned to GFP expression levels that were similar 
to reading Days 1-3.  While this could be interpreted as immediate cell death after 
complete infection, the results of the MTT assay suggest that there is a potential for the 
herbal remedies to be hindering the proliferation of HIV in some way.  Figure 8 includes 
the trends for the HIV experiment along with the trends for the untreated, uninfected 
CEM-GFP controls from all cytotoxicity assays.  As all of the GFP expression levels 
from the HIV assay remain significantly higher than uninfected, untreated CEM-GFP 
cells, the rapid death of cells is unlikely.  However it is possible that for the HIV-infected 
cells, there are fewer viable cells than the uninfected, untreated cells, but that they are 
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fluorescing more brightly thus producing a higher level of GFP expression.  This is not 
very likely, as the MTT assay demonstrates an increased viability in the treated cells 
compared to the negative controls. 
 
Adjustments to HIV Experiment Results based on MTT Results 
Based on the results from the MTT assay, it is important to consider the results of 
the HIV experiment could be influenced by concentration of cells per well.  As the herbal 
treatments in every case appeared to yield a higher number of viable cells in terms of 
absorbance units, this has a possible influence on the GFP expression displayed in the 
HIV experiment.  Although the GFP expressions were not as low in the cytotoxicity 
assays for herbal treatments, the drastic decrease in the HIV experiment creates a need 
for normalization in the number of cells per well.  In order to assess relative changes in 
GFP expression based on the MTT results, the results from the BioTek readout were 
normalized to acknowledge the absorbance unit value for the negative control CEM-GFP 
cells as 1. 
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Table 9. Normalization of the MTT Assay Results to Account for Increased Viability 
and Higher Concentration of Cells in Experimental Treatments. 
 
 
 
 
Considering that a normalization of the MTT assay results gives a relationship regarding 
the ratio of cells treated with herbal remedies to negative control cells, these relationships 
were applied to the GFP expression results given by the HIV experiment.  
 
 
Table 10. Averages from Each Reading Day of HIV Experiment. 
Treatment 
(Conc.) 
Day 1 
Mean 
Day 2 
Mean 
Day 3 
Mean 
Day 4 
Mean 
Day 5 
Mean 
Day 6 
Mean 
Day 7 
Mean 
Control 
(no 
treatment) 
41746.1
7 
40463.4
2 
39920.83 40752.7
5 
38780.5 36200.5 35520.08 
EGT 
(0.1 mmol) 
36295.7
5 
37158.9
2 
38471.17 43202.1
7 
38714 35953.7
5 
36232.67 
AP 
(5 mg/mL) 
29760.1
7 
31758.8
3 
35222.75 44074.6
7 
35467.2
5 
31713 32430.42 
CB 
(1 mg/mL) 
25921.9
2 
26905.1
7 
30677.75 44286.9
2 
31763.9
2 
28182.5
8 
28206 
PPC 
(10 g/ cup) 
23521.5 24153.0
8 
27825.08 44093.5 28512.3
3 
25018.7
5 
25181.42 
CC 
(1/2 
bag/cup) 
22364 22572.3
3 
25770.33 43447.9
2 
26120.4
2 
22976.7
5 
22759.17 
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Table 11. Averages Normalized with Values Determined from the MTT Assay. 
Treatment 
(Conc.) 
Day 1 
Adjust
ed 
Day 2 
Adjust
ed 
Day 3 
Adjuste
d 
Day 4 
Adjust
ed 
Day 5 
Adjust
ed 
Day 6 
Adjust
ed 
Day 7 
Adjuste
d 
Control 
(no 
treatment) 
41746.1
7 
40463.4
2 
39920.83 40752.7
5 
38780.5 36200.5 35520.08 
EGT 
(0.1 mmol) 
16844.3
4973 
17244.9
3485 
17853.93
171 
20049.5
2262 
17966.6
2572 
16685.6
3231 
16815.07
518 
AP 
(5 mg/mL) 
8514.63
6451 
9086.46
9988 
10077.52
681 
12610.1
3602 
10147.4
8033 
9073.35
7637 
9278.617
57 
CB 
(1 mg/mL) 
9598.94
064 
9963.04
015 
11360.03
433 
16399.5
3816 
11762.2
4533 
10436.0
6772 
10444.74
019 
PPC 
(10 g/ cup) 
9437.56
9564 
9690.97
943 
11164.30
194 
17691.7
0646 
11440.0
4837 
10038.3
1361 
10103.58
196 
CC 
(1/2 
bag/cup) 
12478.9
2883 
12595.1
7527 
14379.63
308 
24243.5
8351 
14574.9
8043 
12820.8
3832 
12699.43
046 
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Figure 9. By Dividing the GFP Expression Values by the Normalization Values 
Determined from the MTT Assay, the Trend Graph above was Constructed to 
Account for Higher Concentrations of Cells in Experimental Trials. 
 
 
By taking the increased quantity of cells in the experimental wells according the 
MTT assay results, the effectiveness of the herbal treatments on GFP expression is more 
visible.  An examination of the GFP expression distributed evenly by the theoretical 
number of cells shows that herbal treatments are very effective in decreasing cellular 
stress, namely in the presence of the virus.  However, this is all mathematical speculation 
and would require laboratory confirmation in future trials. 
 
Limitations 
While the preparation of dilutions was meant to mimic the way in which each 
herb was consumed, the use of autoclaved water for solutions possibly hindered the 
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assessment of hydrophobic biologically active compounds in each treatment.  It would 
take a great deal of planning and preparation to mimic in vivo conditions for digestions of 
each herb in vitro. 
Additionally, the conversion of Hypoxis hemerocallidea to rooperol by use of -
Glucosidase was unmonitored, meaning that there is no way of knowing what portion of 
Hypoxis hemerocallidea, if any, was successfully converted to rooperol.  A varying rate 
of conversion would likely produce a different GFP expression, signifying how much 
rooperol is present. 
Lastly, despite quantifiable differences in GFP expression, this assay does not 
provide mechanisms with which to determine the cause of variation in GFP expression.  
There is no definite way of knowing for certain that a decrease in expression signifies 
inhibition of HIV or a decrease in cell viability. However, the latter seems unlikely, 
because the treatments appear to significantly increase the number of viable cells in the 
MTT assays (Chapter V). 
 
Future Research Directions 
 
Future research should involve preparing dilutions to account for hydrophobic 
compounds in each herb.  Also, rooperol should be obtained directly or successfully 
derived prior to experimentation.  Other assays should be used to determine whether or 
not HIV is being actively inhibited. 
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Additionally, herbs should be subjected to separation to determine biologically 
active compounds.  Herbs should also be tested against existing antiretroviral therapies 
for significant interactions to ensure safety of use as complementary herbal remedies.
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APPENDIX A 
 
BIOTEK READOUTS FOR ALL CYTOTOXICITY ASSAY READINGS AND 
ALL HIV EXPERIMENT READINGS 
 
 
Table 12. Day 1 BioTek Readout for Ergothioneine Cytotoxicity Assay 
 
 
 
Table 13. Day 2 BioTek Readout for Ergothioneine Cytotoxicity Assay 
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Table 14. Day 4 BioTek Readout for Ergothioneine Cytotoxicity Assay 
 
 
Table 15. Day 1 BioTek Readout for Hypoxis hemerocallidea Cytotoxicity Assay 
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Table 16. Day 2 BioTek Readout for Hypoxis hemerocallidea Cytotoxicity Assay 
 
 
Table 17.  Day 3 BioTek Readout for Hypoxis hemerocallidea Cytotoxicity Assay 
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Table 18.  Day 1 BioTek Readout for Sutherlandia frutescens Cytotoxicity Assay 
 
 
Table 19. Day 2 BioTek Readout for Sutherlandia frutescens Cytotoxicity Assay 
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Table 20.  Day 3 BioTek Readout for Sutherlandia frutescens Cytotoxicity Assay 
 
 
Table 21. Day 4 BioTek Readout for Sutherlandia frutescens Cytotoxicity Assay 
 
 
Table 22. Day 1 BioTek Readout for Opuntia ficus-indica Cytotoxicity Assay 
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Table 23. Day 2 BioTek Readout for Opuntia ficus-indica Cytotoxicity Assay 
 
 
Table 24. Day 3 BioTek Readout for Opuntia ficus-indica Cytotoxicity Assay 
 
 
Table 25. Day 1 BioTek Readout for Uncaria tomentosa Cytotoxicity Assay 
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Table 26. Day 2 BioTek Readout for Uncaria tomentosa Cytotoxicity Assay 
 
 
Table 27. Day 3 BioTek Readout for Uncaria tomentosa Cytotoxicity Assay 
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Table 28.  Day 1 BioTek Readout for HIV Experiment 
 
 
Table 29. Day 2 BioTek Readout for HIV Experiment 
 
 
Table 30. Day 3 BioTek Readout for HIV Experiment 
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Table 31. Day 4 BioTek Readout for HIV Experiment 
 
 
Table 32. Day 5 BioTek Readout for HIV Experiment 
 
 
Table 33. Day 6 BioTek Readout for HIV Experiment 
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Table 34.  Day 7 BioTek Readout for HIV Experiment 
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APPENDIX B 
 
GRAPHS FOR EACH DAY, DAILY AVERAGES, AND DAILY TRENDS OF 
CYTOTOXICITY ASSAY READINGS AND HIV EXPERIMENT READINGS 
 
Figure 10. Day 1 Daily Readings Graph for Ergothioneine Cytotoxicity Assay 
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Figure 11. Day 1 Daily Averages Graph for Ergothioneine Cytotoxicity Assay 
 
 
 
Figure 12. Day 2 Daily Readings Graph for Ergothioneine Cytotoxicity Assay 
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Figure 13. Day 2 Daily Averages Graph for Ergothioneine Cytotoxicity Assay 
 
 
 
Figure 14. Day 4 Daily Readings Graph for Ergothioneine Cytotoxicity Assay 
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Figure 15. Day 4 Daily Averages Graph for Ergothioneine Cytotoxicity Assay 
 
 
 
Figure 16. Daily Trends for Ergothioneine Cytotoxicity Assay 
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Figure 17. Day 1 Daily Readings Graph for Hypoxis hemerocallidea Cytotoxicity Assay 
 
 
 
Figure 18. Day 1 Daily Averages Graph for Hypoxis hemerocallidea Cytotoxicity Assay 
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Figure 19. Day 2 Daily Readings Graph for Hypoxis hemerocallidea Cytotoxicity Assay 
 
 
 
Figure 20.  Day 2 Daily Averages Graph for Hypoxis hemerocallidea Cytotoxicity Assay 
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Figure 21. Day 3 Daily Readings Graph for Hypoxis hemerocallidea Cytotoxicity Assay 
 
 
 
Figure 22.  Day 3 Daily Averages Graph for Hypoxis hemerocallidea Cytotoxicity Assay 
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Figure 23. Daily Trends Graph for Hypoxis hemerocallidea Cytotoxicity Assay 
 
 
 
Figure 24. Day 1 Daily Readings Graph for Sutherlandia frutescens Cytotoxicity Assay 
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Figure 25. Day 1 Daily Averages Graph for Sutherlandia frutescens Cytotoxicity Assay 
 
 
 
Figure 26. Day 2 Daily Readings Graph for Sutherlandia frutescens Cytotoxicity Assay 
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Figure 27. Day 2 Daily Averages Graph for Sutherlandia frutescens Cytotoxicity Assay 
 
 
 
Figure 28. Day 3 Daily Readings Graph for Sutherlandia frutescens Cytotoxicity Assay 
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Figure 29. Day 3 Daily Averages Graph for Sutherlandia frutescens Cytotoxicity Assay 
 
 
 
Figure 30. Day 4 Daily Readings Graph for Sutherlandia frutescens Cytotoxicity Assay 
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Figure 31. Day 4 Daily Averages Graph for Sutherlandia frutescens Cytotoxicity Assay 
 
 
 
Figure 32. Daily Trends Graph for Sutherlandia frutescens Cytotoxicity Assay 
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Figure 33. Day 1 Daily Readings Graph for Opuntia ficus-indica Cytotoxicity Assay 
 
 
 
Figure 34. Day 1 Daily Averages Graph for Opuntia ficus-indica Cytotoxicity Assay 
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Figure 35. Day 2 Daily Readings Graph for Opuntia ficus-indica Cytotoxicity Assay 
 
 
 
Figure 36.  Day 2 Daily Averages Graph for Opuntia ficus-indica Cytotoxicity Assay 
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Figure 37. Day 3 Daily Readings Graph for Opuntia ficus-indica Cytotoxicity Assay 
 
 
 
Figure 38. Day 3 Daily Averages Graph for Opuntia ficus-indica Cytotoxicity Assay 
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Figure 39. Daily Trends Graph for Opuntia ficus-indica Cytotoxicity Assay 
 
 
 
Figure 40. Day 1 Daily Readings Graph for Uncaria tomentosa Cytotoxicity Assay 
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Figure 41. Day 1 Daily Averages Graph for Uncaria tomentosa Cytotoxicity Assay 
 
 
 
Figure 42. Day 2 Daily Readings Graph for Uncaria tomentosa Cytotoxicity Assay 
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Figure 43. Day 2 Daily Averages Graph for Uncaria tomentosa Cytotoxicity Assay 
 
 
 
Figure 44. Day 3 Daily Readings Graph for Uncaria tomentosa Cytotoxicity Assay 
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Figure 45. Day 3 Daily Averages Graph for Uncaria tomentosa Cytotoxicity Assay 
 
 
 
Figure 46. Daily Trends Graph for Uncaria tomentosa Cytotoxicity Assay 
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Figure 47. Day 1 Daily Readings Graph for HIV Experiment 
 
 
 
Figure 48. Day 1 Daily Averages Graph for HIV Experiment 
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Figure 49. Day 2 Daily Readings Graph for HIV Experiment 
 
 
 
Figure 50. Day 2 Daily Averages Graph for HIV Experiment 
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Figure 51. Day 3 Daily Readings Graph for HIV Experiment 
 
 
 
Figure 52. Day 3 Daily Averages Graph for HIV Experiment 
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Figure 53. Day 4 Daily Readings Graph for HIV Experiment 
 
 
 
Figure 54. Day 4 Daily Averages Graph for HIV Experiment 
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Figure 55. Day 5 Daily Readings Graph for HIV Experiment 
 
 
 
Figure 56. Day 5 Daily Averages Graph for HIV Experiment 
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Figure 57. Day 6 Daily Readings Graph for HIV Experiment 
 
 
 
Figure 58. Day 6 Daily Averages Graph for HIV Experiment 
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Figure 59. Day 7 Daily Readings Graph for HIV Experiment 
 
 
 
Figure 60. Day 7 Daily Averages Graph for HIV Experiment 
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APPENDIX C 
PHOTOGRAPHS OF UNINFECTED VERSUS INFECTED CELLS IN 
BRIGHTFIELD AND GFP IMAGING 
  
Figure 61. Untreated, Uninfected CEM-GFP Cells under Brightfield and GFP Lighting at 10x  
 
 
  
Figure 62. Untreated, HIV-infected CEM-GFP Cells under Brightfield and GFP Lighting at 10x  
 
